ethyl 4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoate | 233283-14-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl 4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoate
• 英文别名: Ethyl 4-[4-(2-pyrimidinyl)-1-piperazinyl)benzoate；ethyl 4-(4-pyrimidin-2-ylpiperazin-1-yl)benzoate
• CAS: 233283-14-2
• 化学式: C₁₇H₂₀N₄O₂
• 分子量: 312.371
• InChiKey: QBPTWJVIRZPGLR-UHFFFAOYSA-N

物化性质

• 沸点：
  519.3±60.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoate 在 manganese(IV) oxide 、 二异丁基氢化铝 、 sodium cyanoborohydride 、 溶剂黄146 、 苯甲醚 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 乙酸乙酯 、 甲苯 为溶剂， 反应 20.0h， 生成 (2S)-benzenesulfonylamino-3-[methyl-[4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzyl]-amino]-propionic acid
  参考文献：
  名称：

  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity

  摘要：

  In order to generate novel compounds with integrin alpha(v)beta(3)-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective alpha(IIb)beta(3) antagonists, replacement of piperazine with piperidine furnished a potent alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonist. Structureactivity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.060
• 作为产物：
  描述：

  对氟苯甲酸乙酯 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 生成 ethyl 4-{4-(pyrimidin-2-yl)-piperazin-1-yl}-benzoate
  参考文献：
  名称：

  Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity

  摘要：

  In order to generate novel compounds with integrin alpha(v)beta(3)-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective alpha(IIb)beta(3) antagonists, replacement of piperazine with piperidine furnished a potent alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonist. Structureactivity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.060

文献信息

• Echinocandin cyclic peptide derivatives
  申请人：Mizuno Hiroaki

  公开号：US20050181988A1

  公开（公告）日：2005-08-18

  This invention relates to new lipopeptide compound represented by the following general formula (I) wherein R 1 , R 2 , R 3 , R4 and R 5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or thereapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal. In particular, R 4 is an alkyl moiety which is substituted with an eventually protected and/or further substituted selected from amino, carboxy, guanidino, heterocyclic-carbonyl, alkyl-carbamoyl.

  本发明涉及一种新的脂肽化合物，其通式如下（I），其中R1、R2、R3、R4和R5如描述中所定义，或其盐具有抗微生物活性（特别是抗真菌活性），对β-1,3-葡聚糖合酶的抑制活性，制备方法，包括它的药物组合物，以及预防和/或治疗包括肺孢子虫感染（例如肺孢子虫肺炎）在人类或动物中的传染病的方法。特别地，R4是一种烷基基团，其被氨基、羧基、鸟氨酸、杂环羰基、烷基氨基酰等保护和/或进一步取代。
• PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN ALPHAvBETA3 ANTAGONISTS
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1057818A1

  公开（公告）日：2000-12-06

  An objective of the present invention is to provide compounds having integrin αvβ3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin αvβ3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.

  本发明的目的是提供具有整合素αvβ3拮抗活性、GPⅡb/Ⅲa拮抗活性和/或人体血小板聚集抑制活性的化合物，以及治疗整合素αvβ3介导的疾病和抑制血小板聚集的治疗剂。根据本发明的衍生物是式 (I) 所代表的化合物或其药学上可接受的盐或溶液： 其中 A 代表含有两个氮原子或类似物的五至七元杂环；X 和 Z 代表 CH 或氮原子；R4 和 R5 代表烷基、卤素或类似物；Q 代表 >C=O、>CH2 或类似物；R6 代表 H、烷基、芳烷基或类似物；R7 代表 H、炔基或类似物；R8 代表 H、取代氨基或类似物；R9 代表 H 或烷基；m 为 0 至 5；n 为 0 至 4；p 为 2 或 3；q 为 0 或 1。
• US6451800B1
  申请人：——

  公开号：US6451800B1

  公开（公告）日：2002-09-17
• [EN] NEW COMPOUND<br/>[FR] NOUVEAU COMPOSE
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003068807A2

  公开（公告）日：2003-08-21

  This invention relates to new lipopeptide compound represented by the following general formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or thereapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal. In particular, R4 is an alkyl moiety which is substituted with an eventually protected and/or further substituted selected from amino, carboxy, guanidino, heterocyclic-carbonyl, alkyl-carbamoyl.
• Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/αIIbβ3 dual antagonistic activity
  作者：Dai Kubota、Minoru Ishikawa、Mikio Yamamoto、Shoichi Murakami、Mitsugu Hachisu、Kiyoaki Katano、Keiichi Ajito

  DOI：10.1016/j.bmc.2005.10.060

  日期：2006.4

  In order to generate novel compounds with integrin alpha(v)beta(3)-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective alpha(IIb)beta(3) antagonists, replacement of piperazine with piperidine furnished a potent alpha(v)beta(3)/alpha(IIb)beta(3) dual antagonist. Structureactivity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists. (c) 2005 Elsevier Ltd. All rights reserved.